The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Determination of the maximum tolerated dose (MTD) of MGCD265, an oral Met/VEGFR multitargeted receptor tyrosine kinase inhibitor, in combination with docetaxel.
D. W. Rasco
Research Funding - MethylGene
A. Patnaik
Research Funding - MethylGene
R. K. Amaravadi
Honoraria - Genentech; Millennium
Research Funding - Millennium; Pfizer
K. P. Papadopoulos
Research Funding - MethylGene
N. B. Haas
No relevant relationships to disclose
A. W. Tolcher
Consultant or Advisory Role - AbGenomics International (U); Abraxis BioScience (U); Actavis (U); Adnexus (U); Ambit BioSciences (U); Amgen (U); ARIAD (U); Arresto (U); Astellas Pharma (U); Bayer (U); BIND Biosciences (U); Biogen Idec (U); Chemokine (U); Curis (U); Dendreon (U); Dicerna (U); Endo Pharmaceuticals (U); Enzon (U); Exelixis (U); FivePrime (U); Genentech (U); Geron (U); GlaxoSmithKline (U); HUYA Bioscience International (U); Insert Therapeutics (U); Intellikine (U); Johnson & Johnson (U); Merck (U); Micromet (U); Nektar (U); Novartis (U); Ortho Biotech (U); Otsuka (U); Pfizer (U); PPD Development (U); ProNAi (U); Regeneron (U); Sanofi (U); Santaris (U); Spectrum Pharmaceuticals (U); SuperGen (U); Symphogen (U); Vaccinex (U); Veeda Oncology (U)
Research Funding - Abbott Laboratories; Adnexus; Ambit BioSciences; Amgen; ArQule; Array BioPharma; Arresto; Astellas Pharma; AVEO; Azaya Therapeutics; Bayer; Biogen Idec; BiPar Sciences; Bristol-Myers Squibb; Calando; Centocor Ortho Biotech; Coronado Biosciences; Cougar Biotechnology; Curis; Cyclacel; Cylene; Daiichi Sankyo; Dendreon; Enzon; Exelixis; FivePrime; Genentech; Genta; GlaxoSmithKline; Hana BioSciences; Immunogen; Lilly; Merck; Merrimack; MethylGene; Millennium; Myrexis; Nektar; Nerviano; Novartis; OncoMed; Onyx; Ortho Biotech; Pfizer; PharmaMar; Proacta; ProNAi; Provia Biologics; Roche; Sanofi ; Schering-Plough; Spectrum Pharmaceuticals; SuperGen; Symphogen; Vaccinex
M. Beeram
No relevant relationships to disclose
K. Harlacker
No relevant relationships to disclose
M. A. Drouin
Consultant or Advisory Role - MethylGene
M. Tawashi
Employment or Leadership Position - MethylGene
J. Wang
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
A. Karam
Employment or Leadership Position - MethylGene
C. R. Maroun
Employment or Leadership Position - MethylGene
C. Bonfils
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
M. Mehran
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
J. M. Besterman
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
P. J. O'Dwyer
Research Funding - MethylGene